濮阳东方男科口碑好服务好(濮阳东方医院治阳痿收费标准) (今日更新中)

SAN FRANCISCO, Oct. 17 (Xinhua) -- Apple on Monday announced that it has sold more than four million of its new iPhone 4S, three days after the launch last Friday."IPhone 4S is off to a great start with more than four million sold in its first weekend--the most ever for a phone and more than double the iPhone 4 launch during its first three days," said Philip Schiller, Apple's senior vice president of worldwide product marketing.In addition, more than 25 million customers are already using iOS 5, the latest version of the mobile operating system powering Apple's mobile devices, since it was released last Wednesday; and more than 20 million customers have signed up for iCloud, the cloud service designed to store and sync data for download to multiple devices, said the company in the statement.The iPhone 4S, which looks the same as the iPhone 4, has major hardware upgrade inside, including a faster chip, a higher- resolution camera and Siri intelligent voice control.Last Friday, AT&T and Sprint, two iPhone wireless carriers in the United States, said they have seen record daily sales with the launch of the iPhone 4S.The lasted Apple smartphone is currently on sale in the U.S., Canada, France, Germany, Japan and Britain, and will be available in 22 more countries on Oct. 28. Apple said the phone will be on sale in more than 70 countries and regions by the end of this year.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Erwinaze to treat patients with acute lymphoblastic leukemia (ALL), who have developed an allergy to E. coli derived asparaginase and pegapargase chemotherapy drugs used to treat ALL.Acute lymphoblastic leukemia is a type of cancer in which the bone marrow makes too many lymphocytes, a type of white blood cell. White blood cells help the body fight infection and are formed in the bone marrow.Erwinaze is injected directly into the muscle three times a week and works by breaking down one of the body's protein building blocks (the amino acid, asparagine) that is present in the blood, and is necessary for the growth of all cells. Leukemia cells cannot produce this protein building block. When a patient is treated with Erwinaze the leukemia cells die. Normal human cells are able to make enough asparagine for their own needs through biosynthesis and will not be affected by treatment with Erwinaze."The approval of Erwinaze underscores the FDA's commitment to the approval of drugs for conditions with limited patient populations with unmet medical needs using novel trial endpoints," said Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research.Side effects associated with Erwinaze treatment include serious allergic reactions, inflammation of the pancreas, high blood levels of liver enzymes, blood clotting, bleeding, nausea, vomiting and high blood sugar.

UNITED NATIONS, Nov. 18 (Xinhua) -- China on Friday voiced its hope that countries concerned "will continue to appropriately address the issue" of the alleged plot to kill Saudi Arabian ambassador to the United States "through dialogue and make joint efforts to maintain peace and stability in the Middle East and the Gulf region."The statement came as Li Baodong, Chinese permanent representative to the United Nations, was addressing the UN General Assembly to explain the Chinese position on the issue after he abstained from voting on the draft resolution on the alleged Iranian involvement in the assassination plot."China hopes countries concerned will continue to appropriately address the issue through dialogue and make joint efforts to maintain peace and stability in the Middle East and the Gulf region," he said."At present, the case is highly complicated and sensitive," Li said. "Parties still have different views over the issue. Any conclusion or action must be based on comprehensive, impartial, objective and transparent investigation and substantial evidence.""Before facts are out, parties should adopt a prudent approach, refrain from jumping to conclusions, and avoid action that may complicate and worsen the situation," he said."China abstained from the vote on the General Assembly draft resolution entitled 'Terrorist Attacks on Internationally Protected Persons'," he said. "We oppose all forms of terrorism, and always stand for compliance with international law and the basis norms governing international relations in handling state-to- state relations as well as effective protection of the safety and security of diplomatic personnel."Earlier on Friday, the UN General Assembly adopted a resolution which expressed deep concerns at the assassination plot and called on Iran "to comply with all of its obligations under international law." Iran strongly denied the allegation.Before or after the vote, countries such as Bolivia, Sudan and Venezuela said that due to a lack of solid evidence to support the allegation, the draft adoption would "create a dangerous precedent " in the international relations.

SAN FRANCISCO, Nov. 9 (Xinhua) -- Cisco Systems Inc., the world 's biggest networking equipment maker, on Wednesday reported that its profit fell about 7.9 percent in the most recent quarter.In the company's fiscal 2012 first quarter ending on Oct. 29, Cisco posted its net income of nearly 1.78 billion U.S. dollars, compared with 1.93 billion dollars in the same period a year earlier.Excluding some items, earnings per share in the quarter were 43 cents, better than the 39 cents estimated by analysts, according to Bloomberg.Cisco's sales in the quarter reached 11.26 billion dollars, an increase of 4.7 percent year-on-year and also topped analysts' projection of about 11 billion dollars."We delivered a solid quarter," John Chambers, Cisco's chief executive officer, said in a statement."We've completed the majority of our restructuring and have organized Cisco to successfully execute against our strategy of providing intelligent networks, architectures and integrated products that solve customers' business problems," he added.

WASHINGTON, Nov. 22 (Xinhua) -- Long-term coffee consumption may be associated with a reduced risk for endometrial cancer, according to a study published online Tuesday in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.Edward Giovannucci, professor of nutrition and epidemiology at the Harvard School of Public Health, said that coffee is emerging as a protective agent in cancers that are linked to obesity, estrogen and insulin."Coffee has already been shown to be protective against diabetes due to its effect on insulin," said Giovannucci, a senior researcher on the study. "So we hypothesized that we'd see a reduction in some cancers as well."The researchers observed cumulative coffee intake in relation to endometrial cancer in 67,470 women who enrolled in the Nurses' Health Study. During the course of 26 years of follow-up, researchers documented 672 cases of endometrial cancer.Drinking more than four cups of coffee per day was linked with a 25 percent reduced risk for endometrial cancer. Drinking between two and three cups per day was linked with a seven percent reduced risk.A similar link was seen in decaffeinated coffee, where drinking more than two cups per day was linked with a 22 percent reduced risk for endometrial cancer.Giovannucci said that he hopes this study will lead to further inquiries about the effect of coffee on cancer because in this and similar studies, coffee intake is self-selected and not randomized.

来源：资阳报